The AIM-listed firm said that the contract with the independent contract manufacturer of therapeutic peptides was signed at the end of March 2018.
READ: Scancell to work with Dutch firm on first on first product for Moditope cancer immune-therapy platform
The cancer specialist said its Moditope platform acts by stimulating the production of CD4+ T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system.
Scancell said it plans to commence a phase I/II clinical trial of Modi-1-AMPLIVANT in the first half of 2019 in patients with triple-negative breast cancer, ovarian cancer and sarcomas.
Cliff Holloway, CEO of Scancell, said: “Commencing GMP manufacture is an important step in the development of our first Moditope product and is key to moving this novel therapy into the clinic in the first half of 2019.”